Plasma therapy trials on Coronavirus patients to begin soon; check details of the COVID-19 procedure

By: |
April 10, 2020 5:37 PM

Plasma therapy trials: An American journal has reported that the therapy has exhibited promising results while treating coronavirus patients.

coronavirus india, coronavirus,covid, coronavirus lockdown, coronavirus vaccine, coronavirus symptoms, coronavirus cure, coronavirus treatment, coronavirus india update, coronavirus india state wise, coronavirus india update live, coronavirus india stage, coronavirus india tracker, coronavirus india cases, coronavirus india wiki, coronavirus india death, covid 19 symptoms, covid,covid 19 india, covid 19 map, covid 19 cases in covid 19 cases in india, covid 19 vaccine, covi india, covid visualizer, covid dashboard india, coronavirus news, coronavirus india state wise count, coronavirus delhi, coronavirus maharashtra, coronavirus kerala, coronavirus italy, coronavirus china. coronavirus USA, narendra modi, coronavirus lockdown india, coronavirus lockdown, coronavirus lockdown india, coronavirus essential services, coronavirus curfew, coronavirus india curfew, coronavirus curfew india, corona india, coronavirus state wiseA member of medical staff swabs the nose of a Palestinian worker for coronavirus disease (COVID-19) testing upon his return from Israel, outside the Israeli-controlled Tarqumiya checkpoint near Hebron. (Courtesy: Reuters photo)

Coronavirus in India: A promising plasma therapy treatment for COVID-19 that involves drawing antibody-rich blood from convalescent, or recovered coronavirus patients, will soon be put through a clinical trial phase in India, a report in the Hindustan Times said. An American journal, Proceedings of the National Academy of Sciences (PNAS), has reported that the therapy has exhibited promising results while treating coronavirus patients, the report adds.

Once the Indian Council of Medical Research (ICMR) earmarks guidelines for the trials, it will seek the approval of the Drugs Controller General of India (DCGI) for running the trials, and once this is received the process will begin. The report quoted Dr Manoj V Murhekar, director, National Institute of Epidemiology, Chennai, as saying that the draft for the trials would be ready in the next few days and it would then have to undergo clinical trial phase as it is a new drug. For this ICMR has to seek the approval of DCGI, he added.

Dr Murhekar opined that these trials have yielded favourable results among limited patients who have been put on ventilator support. He added that though this was not a treatment for all, random patients would be selected and trials would be expedited as the pandemic stage warrants such action.

A patient who has recovered from COVID-19 carries anti-bodies that can neutralise coronavirus, and the plasma from the blood of such persons is transfused into COVID-19 patients to fortify their immune system against the disease.

Meanwhile, the death toll due to the novel coronavirus outbreak in India rose sharply to 199 on Friday, data released by the Health Ministry showed. The total number of COVID-19 cases jumped to 6,412 with the number of active cases stood at 5,709. The MoHFW states that as many as 503 people have been cured and discharged so far and one patient has migrated. Since Thursday evening, the country has recorded at least 30 new deaths, the ministry said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Asymptomatic children have low coronavirus levels compared to those with symptoms, study finds
2Coronavirus India update: Active Covid-19 caseload dips below 7-lakh mark for first time in 2 months
3Delhi CM Arvind Kejriwal lays foundation for new block at LNJP Hospital, hails corona warriors